This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F07%3A00003082%21RIV12-MSM-11120___/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F07%3A00003082%21RIV12-MSM-11120___
rdf:type
skos:Concept n19:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1007/s10557-007-6041-3
dcterms:description
ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction. PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months. In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0. ACE inhibition results in secondary prevention of coronary artery disease (CAD) through different mechanisms including improvement of endothelial dysfunction. The Perindopril-Function of the Endothelium in Coronary artery disease Trial (PERFECT) evaluated whether long-term administration of perindopril improves endothelial dysfunction. PERFECT is a 3-year double blind randomised placebo controlled trial to determine the effect of perindopril 8 mg once daily on brachial artery endothelial function in patients with stable CAD without clinical heart failure. Endothelial function in response to ischaemia was assessed using ultrasound. Primary endpoint was difference in flow-mediated vasodilatation (FMD) assessed at 36 months. In 20 centers, 333 patients randomly received perindopril or matching placebo. Ischemia-induced FMD was 2.7% (SD 2.6). In the perindopril group FMD went from 2.6% at baseline to 3.3% at 36 months and in the placebo group from 2.8 to 3.0%. Change in FMD after 36 month treatment was 0.
dcterms:title
ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial
skos:prefLabel
ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial ACE inhibition and endothelial function: Main findings of PERFECT, a sub-study of the EUROPA trial
skos:notation
RIV/00216208:11120/07:00003082!RIV12-MSM-11120___
n3:aktivita
n5:N n5:V
n3:aktivity
N, V
n3:cisloPeriodika
4
n3:dodaniDat
n10:2012
n3:domaciTvurceVysledku
n8:2228734 n8:8582939
n3:druhVysledku
n9:J
n3:duvernostUdaju
n11:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
408404
n3:idVysledku
RIV/00216208:11120/07:00003082
n3:jazykVysledku
n18:eng
n3:klicovaSlova
ACE inhibition; Atherosclerosis; Brachial reactivity; Cardiovascular disease prevention; Coronary heart disease; Endothelial function
n3:klicoveSlovo
n7:Brachial%20reactivity n7:ACE%20inhibition n7:Atherosclerosis n7:Endothelial%20function n7:Cardiovascular%20disease%20prevention n7:Coronary%20heart%20disease
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[694FB5E07C8D]
n3:nazevZdroje
Cardiovascular Drugs and Therapy
n3:obor
n6:FA
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
45
n3:rokUplatneniVysledku
n10:2007
n3:svazekPeriodika
21
n3:tvurceVysledku
Bots, M. L. Widimský, Petr Špaček, Rudolf
n3:wos
000249402800007
s:issn
0920-3206
s:numberOfPages
11
n16:doi
10.1007/s10557-007-6041-3
n13:organizacniJednotka
11120